Mesoblast - Model MPC-25-Osteo - Phase 3-ready Product for Spinal Fusion
MPC-25-Osteo for spinal fusion is a proprietary Phase 3-ready product candidate. All doses of MPC-25-Osteo for the treatment of spinal fusion consist of 25 million MPCs delivered on a collagen ceramic carrier material into the disc space with stabilizing hardware.
All doses of MPC-25-Osteo for the treatment of spinal fusion consist of 25 million mesenchymal precursor cells (MPCs) delivered on a collagen ceramic carrier material into the disc space with stabilizing hardware. MPC-25-Osteo is a tier 2 product candidate.
Preclinical studies have established that MPCs have anti-inflammatory effects and secrete multiple paracrine factors that stimulate new proteoglycan and collagen synthesis by chondrocytes in vitro and by resident cells in the nucleus and annulus in vivo. MPCs have also been shown to produce anti-inflammation factors. Together these effects offer the potential to strengthen the load bearing function of the disc by improving disc anatomy and stability, while also reducing inflammation and pain.
A spinal fusion surgery is designed to stop the motion at a painful vertebral segment in order to decrease pain generated from the joint.
According to the Millennium Research Group, in the United States there were approximately 392,000 thoracolumbar spinal fusion procedures performed in 2012 of which lumbar fusion procedures form a significant part1.